Table 5.
Integration of anchor-based and distribution-based estimates for Acro-TSQ scales, second study
| Acro-TSQ scale | ||||||
|---|---|---|---|---|---|---|
| Property | Symptom interference | Treatment convenience | Injection site interference | GI interference | Treatment satisfaction | Emotional reaction |
| Minimal detectable change | 9–13 | 8–11 | 10 | 7–12 | 7–10 | 11–12 |
| Regression intercept | − 7 | 6 | – | 8 | 27 | – |
| Acro-TSQ change in EQ-VAS Unchanged group | − 8 | 5 | – | 6 | 6 | – |
| Regression change for 10-point EQ-VAS change | 5 | 6 | – | 6 | 8 | – |
| Regression change for 15-point EQ-VAS change | 7 | 8 | – | 9 | 13 | – |
| Acro-TSQ change in EQ-VAS Much Improved group | 12 | 13 | – | 10 | 28 | – |
| Acro-TSQ change in EQ-VAS Much Worse group | − 14 | − 19 | – | − 11 | − 4 | – |
| MID estimate | 10–12 | 9–11 | – | 8–10 | Undeter-mined | – |
GI gastrointestinal, MID minimally important difference